SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : Full Disclosure Trading

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
Return to Sender
To: Robert O who wrote (13289)9/23/2020 3:40:48 PM
From: Robert O1 Recommendation  Read Replies (1) of 13323
 
IMMU ST-MT BOT 1500 @ 85.21

n.b.
(New York, September 23, 2020 -- Moody's Investors Service ("Moody's") assigned an A3 rating to the new senior unsecured note offering of Gilead Sciences, Inc. ("Gilead"). There are no changes to Gilead's existing A3 senior unsecured ratings, and the outlook remains unchanged at negative. Proceeds of the offering together with cash on hand and proceeds from a new senior unsecured term loan are intended to be used to fund Gilead's pending acquisition of Immunomedics, Inc. and to pay 2021 debt maturities.)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext